Prevalence and Incidence of Anal and Cervical High-Risk Human Papillomavirus (HPV) Types Covered by Current HPV Vaccines Among HIV-Infected Women in the SUN Study
Prevalence and Incidence of Anal and Cervical High-Risk Human Papillomavirus (HPV) Types Covered by Current HPV Vaccines Among HIV-Infected Women in the SUN Study
复制标题
DOI：
10.1093/infdis/jiy087
复制
发表时间：
2018-05-15
影响因子：
6.4
通讯作者：
Patel, Pragna
中科院分区：
文献类型：
--
作者：
Kojic, Erna Milunka;Conley, Lois;Patel, Pragna
背景资料：九价（9v）人乳头瘤病毒疫苗针对高危型人乳头瘤病毒（HR-HPV）16、18、31、33、45、52、58和低危型6、11。我们检查了艾滋病毒感染女性中肛门和宫颈HR-HPV的患病率、发生率和清除率。方法：Sun研究于2004-2006年招募了167名美国女性。每年采集肛门和宫颈标本进行细胞学检查和37种HPV类型的鉴定：14种HR包括：9v 16，18，31，33，45，52，58;非9v 35，39，51，56，59，66，68。67% HIV RNA < 400拷贝/mL; 90% CD 4计数2200个细胞/mm（3）。肛门和宫颈的HPV感染率分别为90%和83%; 9v HR-HPV类型分别为67%和51%;非9v HR-HPV分别为54%和29%。9v和非9v HR-HPV发病率/100人年相似（分别为10.4 vs 9.5; 8.5 vs 8.3）; 9v清除率分别为42%和61%;非9v 46%和59%，在肛门和宫颈，分别。结论：肛门HR-HPV患病率高于宫颈，清除率较低;发病率相似。虽然非9v HR-HPV的流行率很高，但9v HR-HPV类型通常更普遍。这些发现支持在HIV感染妇女中使用九价疫苗。
Background: Nonavalent (9v) human papilloma virus vaccine targets high-risk human papillomavirus (HR-HPV) types 16, 18, 31, 33, 45, 52, 58, and low-risk 6, 11. We examined prevalence, incidence, and clearance of anal and cervical HR-HPV in HIV-infected women.Methods: The SUN Study enrolled 167 US women in 2004-2006. Anal and cervical specimens were collected annually for cytology and identification of 37 HPV types: 14 HR included: 9v 16, 18, 31, 33, 45, 52, 58; non-9v 35, 39, 51, 56, 59, 66, 68.Results: Baseline characteristics of 126 women included: median age 38 years; 57% non-Hispanic black; 67% HIV RNA < 400 copies/mL; 90% CD4 counts 2200 cells/mm(3). HPV prevalence at anus and cervix was 90% and 83%; for 9v HR-HPV types, 67% and 51%; non-9v HR-HPV, 54% and 29%, respectively. The 9v and non-9v HR-HPV incidence rates/100 person-years were similar (10.4 vs 9.5; 8.5 vs 8.3, respectively); 9v clearance rates were 42% and 61%; non-9v 46% and 59%, in anus and cervix, respectively.Conclusions: Anal HR-HPV prevalence was higher than cervical, with lower clearance; incidence was similar. Although prevalence of non-9v HR-HPV was substantial, 9v HR-HPV types were generally more prevalent. Mese findings support use of nonavalent vaccine in HIV-infected women.